You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 14 No. 3, March 1966 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (32)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Effect of Low Molecular Weight Dextran on Cortical Blood Flow

FRANK K. BOSCHENSTEIN, MD; JAMES A. REILLY, MD; MELVIN D. YAHR, MD; JAMES W. CORRELL, MD

Arch Neurol. 1966;14(3):288-293.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

IT IS NOW well recognized that tissue ischemia in the presence of occlusive vascular disease is not only due to the narrowing of arterial channels but to a number of additional factors. One which appears to be of prime importance is an alteration in blood viscosity and red cell mobility within the microvasculature. In both animal experiments and by observations made in humans, Gelin1 has shown that, at low rates of blood flow, viscosity is increased in capillary vessels primarily as a result of the formation of erythrocyte aggregates—the so-called sludging effect. Wells,2 in an extensive review of the rheology of blood in the microvasculature, calls attention to the importance of these changes in a number of clinical conditions and discusses their treatment by the use of pharmacological agents. Though these reports are concerned primarily with various systemic diseases and peripheral vascular disorders, the . . . [Full Text PDF of this Article]


Author Affiliations

NEW YORK

From the departments of neurology and neurological surgery, College of Physicians and Surgeons, Columbia University, and the New York Neurological Institute, New York.


Footnotes

Submitted for publication Sept 10, 1965; accepted Oct 28.

Reprint requests to 710 W 168th St, New York 10032 (Lr. Boschenstein).

Rheomacrodex refers to the low molecular weight dextran used in this study. The average molecular weight of this substance is about 40,000. The ordinary dextran plasma expander has an average molecular weight of about 75,000. The properties of dextran are to a high degree dependent upon the molecular weight.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1966 American Medical Association. All Rights Reserved.